Evidence map›Paper›PMID 25359988›Full record

Trial reportBlood2014

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.

Dieter Hoelzer, Jan Walewski, Hartmut Döhner, Andreas Viardot, Wolfgang Hiddemann, Karsten Spiekermann, Hubert Serve, Ulrich Dührsen, Andreas Hüttmann, Eckhard Thiel and 15 more

Registry-linked trialOpen access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00199082 (Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults), which is not on this map. Cited by 107 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 3 pooled it
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00199082 phase4completednot on this map

Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7)

TypeinterventionalSponsorNicola GoekbugetRan2002 to 2010Enrolled650ConditionsBurkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Neoplasms, Lymphoblastic LymphomaArmsAdriamycin, Cyclophosphamide, Cytarabine, Dexamethasone/Prednisolone, VP16
3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 3 syntheses or guidelines pooled it, 297 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Primary lacrimal sac Burkitt lymphoma: A case report and literature review.American journal of ophthalmology case reports · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. 2-[Annals of hematology · 2024
    Article
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 13 institutions in 2 countries.

Dieter HoelzerDepartment of Internal Medicine II, Hematology and Oncology, University Hospital, Frankfurt, Germany;
Jan WalewskiDepartment of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland;
Hartmut DöhnerDepartment of Internal Medicine III, University Hospital, Ulm, Germany;
Andreas ViardotDepartment of Internal Medicine III, University Hospital, Ulm, Germany;
Wolfgang HiddemannDepartment of Medicine III, Clinic Grosshadern, Munich, Germany;
Karsten SpiekermannDepartment of Medicine III, Clinic Grosshadern, Munich, Germany;
Hubert ServeDepartment of Internal Medicine II, Hematology and Oncology, University Hospital, Frankfurt, Germany;
Ulrich DührsenDepartment of Hematology and Oncology, University Hospital, Essen, Germany;
Andreas HüttmannDepartment of Hematology and Oncology, University Hospital, Essen, Germany;
Eckhard ThielDepartment of Hematology, Oncology, and Tumorimmunology, Charité Campus Benjamin Franklin, Berlin, Germany;
Jolanta DenglerDepartment of Internal Medicine V, University of Heidelberg, Germany;
Michael KnebaDepartment of Internal Medicine II, University Hospital of Schleswig Holstein, Campus Kiel, Kiel, Germany;
Markus SchaichDepartment of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany;
Ingo G H Schmidt-WolfDepartment of Internal Medicine III, University of Bonn, Bonn, Germany;
Joachim BeckDepartment of Medicine II, University Hospital, Mainz, Germany;
Bernd HertensteinDepartment of Internal Medicine I, Clinic Bremen-Mitte, Bremen, Germany;
Albrecht ReichleDepartment of Hematology/Oncology, University Hospital, Regensburg, Germany;
Katarzyna Domanska-CzyzDepartment of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland;
Rainer FietkauInstitute for Radiotherapy, University Hospital, Erlangen, Germany; and.
Heinz-August HorstDepartment of Internal Medicine II, University Hospital of Schleswig Holstein, Campus Kiel, Kiel, Germany;
Harald RiederInstitute for Human Genetics, University Clinic, Duesseldorf, Germany.
Stefan SchwartzDepartment of Hematology, Oncology, and Tumorimmunology, Charité Campus Benjamin Franklin, Berlin, Germany;
Thomas BurmeisterDepartment of Hematology, Oncology, and Tumorimmunology, Charité Campus Benjamin Franklin, Berlin, Germany;
Nicola GökbugetDepartment of Internal Medicine II, Hematology and Oncology, University Hospital, Frankfurt, Germany;
German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Charité - Universitätsmedizin Berlin · DEGoethe University Frankfurt · DEEssen University Hospital · DEThe Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversity Hospital Schleswig-Holstein · DEUniversity Hospital Ulm · DEDüsseldorf University Hospital · DEHeidelberg University · DEKlinikum Bremen-Mitte · DEUniversitätsklinikum Erlangen · DEUniversity Hospital Carl Gustav Carus · DEUniversity Hospital Regensburg · DEUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This largest prospective multicenter trial for adult patients with Burkitt lymphoma/leukemia aimed to prove the efficacy and feasibility of short-intensive chemotherapy combined with the anti-CD20 antibody rituximab. From 2002 to 2011, 363 patients 16 to 85 years old were recruited in 98 centers. Treatment consisted of 6 5-day chemotherapy cycles with high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, ifosphamide, corticosteroids, and triple intrathecal therapy. Patients >55 years old received a reduced regimen. Rituximab was given before each cycle and twice as maintenance, for a total of 8 doses. The rate of complete remission was 88% (319/363); overall survival (OS) at 5 years, 80%; and progression-free survival, 71%; with significant difference between adolescents, adults, and elderly patients (OS rate of 90%, 84%, and 62%, respectively). Full treatment could be applied in 86% of the patients. The most important prognostic factors were International Prognostic Index (IPI) score (0-2 vs 3-5; P = .0005), age-adjusted IPI score (0-1 vs 2-3; P = .0001), and gender (male vs female; P = .004). The high cure rate in this prospective trial with a substantial number of participating hospitals demonstrates the efficacy and feasibility of chemoimmunotherapy, even in elderly patients. This trial was registered at www.clinicaltrials.gov as #NCT00199082.

Indexed as

AdolescentAdrenal Cortex HormonesAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antineoplastic Combined Chemotherapy ProtocolsBurkitt LymphomaCyclophosphamideCytarabineDisease-Free SurvivalEtoposideFemaleHumansIfosfamideAdrenal Cortex HormonesAntibodies, Monoclonal, Murine-DerivedAntigens, CD20CyclophosphamideCytarabineEtoposideIfosfamideMethotrexateRituximab

Identifiers

PMID25359988
PMCPMC4271177
OpenAlexW2047522348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.